- 8 Downloads
▲ Edobacomab is a murine monoclonal antibody (IgM) directed against the lipid A moiety of endotoxin from Gram-negative bacteria.
▲ Edobacomab reduces circulating levels of endotoxin [lipopolysaccharide (LPS)] and tumour necrosis factor in vivo.
▲ Animal studies have shown that edobacomab improves survival and protects against the haemodyna-mic consequences of LPS challenge.
▲ Data from an early phase III clinical study suggested that edobacomab may improve survival in patients with Gram-negative sepsis who are not in refractory shock. These results were, however, not substantiated in a later study. The drug appears to enhance resolution of organ failure in patients with Gram-negative infection.
▲ Approximately 40 to 50% of patients may develop delayed antimurine antibody responses after administration of edobacomab. These have not been associated with clinical symptoms.
KeywordsAdis International Limited Adult Respiratory Distress Syndrome Murine Monoclonal Antibody Refractory Shock Negative Sepsis
Unable to display preview. Download preview PDF.
- 2.Lynn WA. Prospects for the immunotherapy of septic shock. Curr Opin Invest Drugs 1993 Sep; 2: 973–81Google Scholar
- 3.Quintiliani R, Cooper B, Maderazo E, et al. Gram-negative sepsis: pathophysiology of infection, development of polyclonal, monoclonal human hybrid and murine anti-endotoxin antibodies. Hosp Formul 1991; 26(12): 960–8Google Scholar
- 10.Neely AN, Orloff MM, Imwalle AR, et al. A murine model for studying endotoxemia and the efficacy of anti-LPS agents in an immunocompromised host. J Endotoxin Res 1995; 2(2): 115–20Google Scholar
- 28.Perl TM, Dvorak L, Fu CM, et al. Long-term, post-hospital survival after sepsis: influence of antiendotoxin antibody (E5) [abstract]. 33rd Interscience Conference Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, USA, 1993 Oct 17–20: 246Google Scholar